Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice

被引:32
|
作者
von Buedingen, Fiona [1 ]
Hammer, Marc S. [1 ]
Meid, Andreas D. [2 ]
Mueller, Walter E. [3 ]
Gerlach, Ferdinand M. [1 ]
Muth, Christiane [1 ]
机构
[1] Goethe Univ Frankfurt, Inst Gen Practice, Theodor Stern Kai 7, D-60590 Frankfurt, Main, Germany
[2] Heidelberg Univ, Dept Clin Pharmacol & Pharmacoepidemiol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany
[3] Goethe Univ Frankfurt, Pharmacol Inst Nat Scientists, Max von Laue Str 9, D-60438 Frankfurt, Germany
来源
BMC FAMILY PRACTICE | 2018年 / 19卷
关键词
Medication changes; Polypharmacy; Older adults; General practice; Multiple chronic conditions; Multimorbidity; MEDICATION REGIMEN COMPLEXITY; RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE ASSISTANTS; ADVERSE DRUG-REACTIONS; ILLNESS RATING-SCALE; QUALITY-OF-LIFE; CASE-MANAGEMENT; ELDERLY-PEOPLE; THERAPY; APPROPRIATENESS;
D O I
10.1186/s12875-018-0825-3
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Treatment complexity rises in line with the number of drugs, single doses, and administration methods, thereby threatening patient adherence. Patients with multimorbidity often need flexible, individualised treatment regimens, but alterations during the course of treatment may further increase complexity. The objective of our study was to explore medication changes in older patients with multimorbidity and polypharmacy in general practice. Methods: We retrospectively analysed data from the cluster-randomised PRIMUM trial (PRIoritisation of MUltimedication in Multimorbidity) conducted in 72 general practices. We developed an algorithm for active pharmaceutical ingredients (API), strength, dosage, and administration method to assess changes in physician-reported medication data during two intervals (baseline to six-months Delta(1); six-to nine-months Delta(2)), analysed them descriptively at prescription and patient levels, and checked for intervention effects. Results: Of 502 patients (median age 72 years, 52% female), 464 completed the study. Changes occurred in 98.6% of patients (changes were 19% more likely in the intervention group): API changes during Delta(1) and Delta(2) occurred in 414 (82.5%) and 338 (67.3%) of patients, dosage alterations in 372 (74.1%) and 296 (59.2%), and changes in API strength in 158 (31.5%) and 138 (27.5%) respectively. Administration method changed in 79 (16%) of patients in both Delta(1) and Delta(2). Simvastatin, metformin and aspirin were most frequently subject to alterations. Conclusion: Medication regimens in older patients with multimorbidity and polypharmacy changed frequently. These are mostly due to discontinuations and dosage alterations, followed by additions and restarts. These findings cast doubt on the effectiveness of cross-sectional assessments of medication and support longitudinal assessments where possible.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice
    Fiona von Buedingen
    Marc S. Hammer
    Andreas D. Meid
    Walter E. Müller
    Ferdinand M. Gerlach
    Christiane Muth
    BMC Family Practice, 19
  • [2] A systematic review of general practice-based pharmacists' services to optimize medicines management in older people with multimorbidity and polypharmacy
    Ibrahim, Ameerah S. Hasan
    Barry, Heather E.
    Hughes, Carmel M.
    FAMILY PRACTICE, 2021, 38 (04) : 509 - 523
  • [3] Multimorbidity, polypharmacy, and mortality in older patients with pacemakers
    Goto, Toshihiko
    Mori, Kento
    Nakayama, Takafumi
    Yamamoto, Junki
    Shintani, Yasuhiro
    Wakami, Kazuaki
    Fukuta, Hidekatsu
    Seo, Yoshihiro
    Ohte, Nobuyuki
    JOURNAL OF ARRHYTHMIA, 2022, 38 (01) : 145 - 154
  • [4] Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice
    Mueller, Beate S.
    Uhlmann, Lorenz
    Ihle, Peter
    Stock, Christian
    von Buedingen, Fiona
    Beyer, Martin
    Gerlach, Ferdinand M.
    Perera, Rafael
    Valderas, Jose Maria
    Glasziou, Paul
    van den Akker, Marjan
    Muth, Christiane
    BMJ OPEN, 2020, 10 (10):
  • [5] Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
    Reeve, Joanne
    Maden, Michelle
    Hill, Ruaraidh
    Turk, Amadea
    Mahtani, Kamal
    Wong, Geoff
    Lasserson, Dan
    Krska, Janet
    Mangin, Dee
    Byng, Richard
    Wallacc, Emma
    Ranson, Ed
    HEALTH TECHNOLOGY ASSESSMENT, 2022, 26 (32) : 1 - +
  • [6] Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review
    O'Shea, Joseph
    Ledwidge, Mark
    Gallagher, Joseph
    Keenan, Catherine
    Ryan, Cristin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (06) : 1795 - 1795
  • [7] Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review
    O'Shea, Joseph
    Ledwidge, Mark
    Gallagher, Joseph
    Keenan, Catherine
    Ryan, Cristin
    PHARMACOGENOMICS JOURNAL, 2022, 22 (02): : 89 - 99
  • [8] Management of polypharmacy in older people with multimorbidity
    Hoffmann, Ute
    INNERE MEDIZIN, 2024, 65 (01): : 9 - 16
  • [9] Multimorbidity and polypharmacy in hospitalized older patients: a cross-sectional study
    Zhao, Yong
    Wang, Jianchun
    Zhu, Xiaojuan
    Zhang, Xiyu
    Zhang, Yahui
    Zhang, Wen
    Dong, Yan
    BMC GERIATRICS, 2023, 23 (01)
  • [10] Health professional perspectives on the management of multimorbidity and polypharmacy for older patients in Australia
    Mc Namara, Kevin Peter
    Breken, Bianca Daphne
    Alzubaidi, Hamzah Tariq
    Bell, J. Simon
    Dunbar, James A.
    Walker, Christine
    Hernan, Andrea
    AGE AND AGEING, 2017, 46 (02) : 291 - 299